Last 47 quarters of trend data · Healthcare · Drug Manufacturers - Specialty & Generic
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q1 '27 | Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.59 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 0.10 | 0.18 | 0.17 | 0.36 | 0.28 | 0.29 | 0.18 | 0.28 | 0.22 | 0.27 | 0.19 | 0.16 | 0.73 | 0.77 | 0.76 | 0.59 | 0.99 | 1.14 | 2.42 | 2.42 | 1.75 |
| — | -36.6% | -6.7% | +29.8% | +28.5% | +9.4% | -4.2% | +76.1% | -69.6% | -65.5% | -75.1% | -73.5% | -26.4% | -32.2% | -68.6% | -75.6% | -43.2% | -45.5% | -32.7% | +60.4% | +11.5% | |
| P/B Ratio | 0.60 | 0.72 | 1.21 | 1.82 | 1.69 | 1.15 | 0.62 | 0.81 | 0.59 | 0.73 | 0.42 | 0.29 | 1.40 | 1.46 | 1.15 | 1.25 | 1.88 | 2.28 | 2.55 | 2.51 | 2.28 |
| — | -37.8% | +97.1% | +124.7% | +184.3% | +58.9% | +45.5% | +174.8% | -57.8% | -50.2% | -63.0% | -76.5% | -25.3% | -35.9% | -55.2% | -50.2% | -17.6% | -65.8% | -55.8% | +4.0% | -27.0% | |
| P/FCF | — | — | — | — | — | — | 1.21 | 3.00 | 2.42 | — | 4.19 | 0.87 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | -71.2% | +243.3% | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q1 '27 | Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 38.0% | 40.2% | 39.2% | 37.9% | 37.8% | 36.5% | 40.7% | 35.6% | 38.0% | 38.5% | 31.7% | 46.5% | 36.3% | 35.1% | 28.7% | 28.2% | 46.1% | 41.3% | 4.2% | 41.5% | 33.1% |
| — | +10.3% | -3.6% | +6.5% | -0.5% | -5.3% | +28.3% | -23.4% | +4.9% | +9.6% | +10.7% | +64.8% | -21.4% | -15.0% | +586.2% | -31.9% | +39.1% | +4.8% | +146.4% | +2.6% | -23.6% | |
| Operating Margin | -12.6% | -0.6% | -6.3% | -15.6% | -6.0% | -27.3% | -17.5% | -28.9% | -23.7% | -34.6% | -41.0% | -26.9% | -44.2% | -36.2% | -38.1% | -62.3% | -21.9% | -21.5% | -133.2% | -33.0% | -25.7% |
| — | +97.7% | +63.9% | +46.1% | +74.7% | +21.2% | +57.3% | -7.6% | +46.3% | +4.4% | -7.7% | +56.8% | -101.6% | -68.6% | +71.4% | -88.7% | +14.8% | +12.5% | -2.1% | -1080.8% | -978.9% | |
| Net Margin | -16.3% | -5.2% | -10.4% | -18.8% | -9.5% | -30.9% | -20.7% | -26.0% | -17.0% | -33.7% | -31.0% | -27.6% | -54.3% | -41.4% | -43.4% | -65.9% | -30.5% | -22.3% | -128.1% | -32.5% | -2.7% |
| — | +83.3% | +49.5% | +27.7% | +44.1% | +8.3% | +33.4% | +5.6% | +68.6% | +18.5% | +28.5% | +58.1% | -78.0% | -85.8% | +66.1% | -102.5% | -1043.1% | +25.3% | +24.5% | -147.0% | -228.4% |
| Metric | TTM | Q1 '27 | Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -84.6% | -6.8% | -17.8% | -22.7% | -13.6% | -29.3% | -16.7% | -18.2% | -11.8% | -20.6% | -16.6% | -14.0% | -23.0% | -18.6% | -19.3% | -30.8% | -13.6% | -10.7% | -29.6% | -8.3% | -1.2% |
| — | +76.8% | -6.5% | -25.0% | -15.3% | -42.5% | -0.5% | -29.6% | +48.6% | -10.4% | +13.9% | +54.6% | -69.2% | -75.0% | +34.8% | -269.5% | -991.8% | +51.6% | +28.4% | -53.2% | -219.0% | |
| ROA | -23.0% | -2.1% | -4.2% | -6.0% | -3.8% | -8.8% | -5.7% | -6.8% | -4.5% | -8.0% | -7.3% | -6.1% | -10.1% | -8.8% | -8.7% | -13.4% | -6.3% | -4.9% | -15.4% | -4.8% | -0.6% |
| — | +76.5% | +25.7% | +12.2% | +15.8% | -9.1% | +22.0% | -10.7% | +55.6% | +8.9% | +16.2% | +54.3% | -58.7% | -79.2% | +43.7% | -178.5% | -974.9% | +34.7% | +30.0% | -34.9% | -190.3% | |
| ROIC | -419.5% | -1.7% | -17.2% | -36.2% | -20.9% | -351.0% | — | -121.7% | -29.5% | -27.4% | -25.5% | -14.5% | -21.5% | -19.9% | -20.4% | -35.0% | -14.1% | -21.4% | -70.4% | -17.1% | -16.4% |
| — | +99.5% | — | +70.3% | +29.0% | -1181.2% | — | -739.1% | -36.9% | -37.8% | -24.8% | +58.6% | -52.6% | +7.1% | +71.0% | -104.8% | +14.2% | -27.2% | -109.8% | -1388.0% | -1270.7% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q1 '27 | Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.27 | 0.11 | 0.27 | 0.19 | 0.14 | 0.17 | 0.07 | 0.02 | 0.05 | 0.08 | 0.10 | 0.06 | 0.09 | 0.09 | 0.11 | 0.09 | 0.11 | 0.12 | 0.16 | 0.11 | 0.13 |
| — | -32.7% | +293.5% | +681.1% | +209.9% | +97.1% | -30.2% | -57.5% | -50.4% | -6.7% | -6.9% | -34.2% | -16.6% | -24.4% | -32.3% | -19.3% | -15.0% | -77.2% | -68.5% | -32.6% | -25.6% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 2.50 | 2.99 | 2.50 | 2.88 | 2.89 | 2.70 | 3.09 | 3.34 | 3.69 | 3.18 | 3.37 | 4.07 | 3.56 | 3.36 | 3.71 | 2.86 | 3.51 | 3.05 | 2.82 | 4.57 | 4.42 |
| — | +10.5% | -18.9% | -13.9% | -21.7% | -15.0% | -8.5% | -17.8% | +3.9% | -5.4% | -9.1% | +42.4% | +1.2% | +10.1% | +31.5% | -37.5% | -20.5% | +31.4% | -11.3% | +9.4% | +24.1% | |
| Quick Ratio | 1.75 | 2.29 | 1.75 | 2.00 | 2.05 | 1.92 | 2.38 | 2.49 | 2.84 | 2.47 | 2.64 | 3.11 | 2.78 | 2.69 | 2.94 | 2.13 | 2.66 | 2.48 | 2.37 | 3.82 | 3.81 |
| — | +19.4% | -26.4% | -19.7% | -27.7% | -22.3% | -10.1% | -19.7% | +2.0% | -8.0% | -10.2% | +45.7% | +4.6% | +8.4% | +24.4% | -44.3% | -30.3% | +36.0% | -7.7% | +12.0% | +38.6% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -363.67 | — | -22.75 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying SNOA stock.
Sonoma Pharmaceuticals, Inc.'s current P/E is -0.6x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Sonoma Pharmaceuticals, Inc.'s current operating margin is -12.6%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Sonoma Pharmaceuticals, Inc.'s business trajectory between earnings reports.